Levemir is being phased out: why there’s time, and how switches are planned
Levemir (insulin detemir), a background insulin, is being discontinued worldwide, with UK stock expected to run out by the end of 2026.
If Levemir is your background insulin, it is being discontinued, but there is nothing to sort out today and no reason to worry. Levemir (insulin detemir) is a basal insulin, the slow background insulin that works quietly all day and night. UK stock is expected to last until the end of 2026, and teams are moving people gradually onto another long-acting insulin well before then. The one thing that matters from you: keep your review appointment, because a change of background insulin can need a dose check, and that is worked out with your team, never off a website.
- Levemir (insulin detemir) is a basal insulin, the background insulin that runs steadily between meals and overnight.
- It is being discontinued worldwide, with UK stock expected to run out by the end of 2026.
- There is a long runway: teams are switching people gradually, aiming to finish before supplies end.
- The replacement is another long or intermediate insulin (such as glargine, degludec or isophane), and it may not be a like-for-like swap, so a dose review can be part of it.
- Do not stockpile or self-adjust: your team plans the switch and works out the new dose with you.
What is being discontinued, and the timeline
Levemir, the brand name for insulin detemir, is being discontinued worldwide. In the UK, stock is expected to be used up by the end of 2026. This has been signposted well in advance precisely so it can be handled as a planned change rather than a sudden gap, and specialist bodies have issued guidance to teams on how to move people across.
So this is not a shortage that leaves you scrambling. It is a long, managed wind-down. Teams are switching people who use Levemir onto a different background insulin gradually, over the runway between now and the end of 2026, aiming to have everyone moved before supplies run out. There is no need to rush, and no need to stockpile: stockpiling only makes supply tighter for other people.
Why a basal switch is done with your team, not off a number
The replacement will be another long or intermediate acting insulin, such as glargine, degludec or isophane. These are all background insulins, but they are not identical to Levemir: some last a different length of time, and some are taken once a day where Levemir is often taken twice. That is exactly why a switch can involve a review of your dose, and why it is a decision made with your team rather than something you read off a chart.
What you can do is be an active part of it. Keep the review appointment when it comes, and after the switch, keep an eye on your numbers. If you see a run of unexpected highs or lows, especially overnight when the background insulin is doing most of its work, that is information to take back to your team. It is not a sign you have done anything wrong, and it is not something to fix yourself by changing the dose.